804 reports of this reaction
3.3% of all TOLVAPTAN reports
#3 most reported adverse reaction
RENAL IMPAIRMENT is the #3 most commonly reported adverse reaction for TOLVAPTAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 804 FDA adverse event reports linking TOLVAPTAN to RENAL IMPAIRMENT. This represents approximately 3.3% of all 24,584 adverse event reports for this drug.
Patients taking TOLVAPTAN who experience renal impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL IMPAIRMENT is moderately reported among TOLVAPTAN users, representing a notable but not dominant share of adverse events.
In addition to renal impairment, the following adverse reactions have been reported for TOLVAPTAN:
The following drugs have also been linked to renal impairment in FDA adverse event reports:
RENAL IMPAIRMENT has been reported as an adverse event in 804 FDA reports for TOLVAPTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL IMPAIRMENT accounts for approximately 3.3% of all adverse event reports for TOLVAPTAN, making it one of the most commonly reported side effect.
If you experience renal impairment while taking TOLVAPTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.